Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ELA elimination final rule drops "well characterized" definition; FDA expands list of eligible biologics.

Executive Summary

FDA BROADENS LIST OF NON-ELA BIOLOGICAL PRODUCT CATEGORIES in a final rule eliminating the requirement for establishment licensing applications for certain biologics published in the Federal Register May 14. The rule eliminates ELA requirements for therapeutic DNA plasmid products, therapeutic synthetic peptide products of 40 or fewer amino acids, monoclonal antibody products for in vivo use and therapeutic recombinant DNA-derived products.

You may also be interested in...

Biologics Applicants Are Responsible For Contract Facility Compliance - FDA

Biologics license applicants will be held responsible for contractor deviations from cGMPs, FDA says in an updated draft "Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics."

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts